Logo image of RGC

REGENCELL BIOSCIENCE HOLDING (RGC) Stock Fundamental Analysis

NASDAQ:RGC - Nasdaq - KYG7487R1002 - Common Stock - Currency: USD

595.1  -15.4 (-2.52%)

Fundamental Rating

3

Taking everything into account, RGC scores 3 out of 10 in our fundamental rating. RGC was compared to 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for RGC as it has an excellent financial health rating, but there are worries on the profitability. RGC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RGC has reported negative net income.
RGC had a negative operating cash flow in the past year.
In the past 5 years RGC always reported negative net income.
In the past 5 years RGC always reported negative operating cash flow.
RGC Yearly Net Income VS EBIT VS OCF VS FCFRGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

The Return On Assets of RGC (-51.07%) is worse than 60.00% of its industry peers.
Looking at the Return On Equity, with a value of -52.43%, RGC is in line with its industry, outperforming 52.82% of the companies in the same industry.
Industry RankSector Rank
ROA -51.07%
ROE -52.43%
ROIC N/A
ROA(3y)-46.27%
ROA(5y)-138.94%
ROE(3y)-48.25%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RGC Yearly ROA, ROE, ROICRGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RGC Yearly Profit, Operating, Gross MarginsRGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

9

2. Health

2.1 Basic Checks

RGC has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for RGC has been increased compared to 5 years ago.
RGC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RGC Yearly Shares OutstandingRGC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
RGC Yearly Total Debt VS Total AssetsRGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

RGC has an Altman-Z score of 21657.28. This indicates that RGC is financially healthy and has little risk of bankruptcy at the moment.
RGC has a Altman-Z score of 21657.28. This is amongst the best in the industry. RGC outperforms 100.00% of its industry peers.
There is no outstanding debt for RGC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21657.28
ROIC/WACCN/A
WACCN/A
RGC Yearly LT Debt VS Equity VS FCFRGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

RGC has a Current Ratio of 42.68. This indicates that RGC is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 42.68, RGC belongs to the best of the industry, outperforming 98.97% of the companies in the same industry.
RGC has a Quick Ratio of 42.68. This indicates that RGC is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 42.68, RGC belongs to the best of the industry, outperforming 98.97% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 42.68
Quick Ratio 42.68
RGC Yearly Current Assets VS Current LiabilitesRGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.67% over the past year.
EPS 1Y (TTM)26.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGC Price Earnings VS Forward Price EarningsRGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGC Per share dataRGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RGC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGENCELL BIOSCIENCE HOLDING

NASDAQ:RGC (6/13/2025, 8:00:02 PM)

595.1

-15.4 (-2.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners0.29%
Inst Owner Change-72.02%
Ins Owners81.22%
Ins Owner Change0%
Market Cap7.74B
Analysts63.4
Price TargetN/A
Short Float %4.45%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 941.88
P/tB 941.88
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.07%
ROE -52.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.27%
ROA(5y)-138.94%
ROE(3y)-48.25%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.23%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 42.68
Quick Ratio 42.68
Altman-Z 21657.28
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.86%
Cap/Depr(5y)346.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.35%
OCF growth 3YN/A
OCF growth 5YN/A